C4 Therapeutics Inc

NASDAQ:CCCC   3:59:59 PM EDT
38.00
+0.92 (+2.48%)
Products, Regulatory

C4 Therapeutics Presents Pre-Clinical Data On CFT8919 At Keystone Symposium On Targeted Protein Degradation

Published: 06/07/2021 11:39 GMT
C4 Therapeutics Inc (CCCC) - C4 Therapeutics Presents Pre-clinical Data on Cft8919, a Selective Degrader of Egfr L858r, at Keystone Symposium on Targeted Protein Degradation.
C4 Therapeutics Inc - Cft8919 Demonstrates Intracranial Activity Pre-clinically, Indicating Potential to Be Effective Against Cns Metastases.
C4 Therapeutics - Pre-clinical Data Support Plans to Advance Cft8919 to Clinical Development With Ind Submission Expected in Mid-2022 and Clinical Trial Initiation Expected by Ye 2022.